Get the Stockscreener App
0.518
1.52%
-0.008
After Hours:
.57
0.052
+10.04%
Biodesix Inc stock is traded at $0.518, with a volume of 240.79K.
It is down -1.52% in the last 24 hours and down -17.48% over the past month.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
See More
Previous Close:
$0.526
Open:
$0.54
24h Volume:
240.79K
Relative Volume:
0.72
Market Cap:
$78.68M
Revenue:
$49.09M
Net Income/Loss:
$-52.15M
P/E Ratio:
-0.7969
EPS:
-0.65
Net Cash Flow:
$-45.93M
1W Performance:
-3.90%
1M Performance:
-17.48%
6M Performance:
-60.15%
1Y Performance:
-60.46%
1-Day Range:
$0.513
$0.58
1-Week Range:
$0.5105
$0.5995
52-Week Range:
$0.45
$2.04
Biodesix Inc Stock (BDSX) Company Profile
Name
Biodesix Inc
Sector
Industry
Phone
303-417-0500
Address
919 WEST DILLON ROAD, LOUISVILLE
Compare BDSX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
0.518 | 78.68M | 49.09M | -52.15M | -45.93M | -0.65 |
|
TMO
Thermo Fisher Scientific Inc
|
423.55 | 160.15B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
199.05 | 141.09B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
471.90 | 35.45B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
108.63 | 30.37B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
153.48 | 26.50B | 15.41B | 1.37B | 2.11B | 7.50 |
Biodesix Inc Stock (BDSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-26-24 | Initiated | Craig Hallum | Buy |
| May-13-24 | Initiated | TD Cowen | Buy |
| May-03-24 | Initiated | Lake Street | Buy |
| Nov-17-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-23-20 | Initiated | BTIG Research | Buy |
| Nov-23-20 | Initiated | Canaccord Genuity | Buy |
| Nov-23-20 | Initiated | Morgan Stanley | Overweight |
| Nov-23-20 | Initiated | William Blair | Outperform |
View All
Biodesix Inc Stock (BDSX) Latest News
Biodesix, Inc. (NASDAQ:BDSX) Receives $2.95 Average Target Price from Analysts - Defense World
Biodesix, Inc. (NASDAQ:BDSX) Receives $2.95 Average Price Target from Brokerages - MarketBeat
Canaccord Genuity Group Lowers Biodesix (NASDAQ:BDSX) Price Target to $2.50 - MarketBeat
Geode Capital Management LLC Increases Position in Biodesix, Inc. (NASDAQ:BDSX) - Defense World
Biodesix (BDSX) Target Price Reduced by Canaccord Amid Market Ch - GuruFocus
Wells Fargo & Company MN Has $1.28 Million Holdings in Biodesix, Inc. (NASDAQ:BDSX) - Defense World
Biodesix to Report First Quarter 2025 Financial Results on May 1 - GuruFocus
Biodesix, Inc. to Release First Quarter 2025 Financial Results on May 13 - Nasdaq
Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025 - Bluefield Daily Telegraph
Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025 - GlobeNewswire Inc.
Biodesix and Bio-Rad Drive Advances in ctDNA-Based Cancer Therapies - Technology Networks
Ratios Uncovered: Breaking Down Biodesix Inc (BDSX)’s Trailing Twelve Months Metrics - DWinneX
Silverarc Capital Management LLC Acquires 771,187 Shares of Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat
Biodesix Inc (BDSX) Stock: From Low to High in 52 Weeks - investchronicle.com
Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types - MSN
Biodesix Inc [BDSX] Chief Accounting Officer makes an insider purchase of 3,630 shares worth 3355.0. - knoxdaily.com
Biodesix and Bio-Rad publish data linking ctDNA changes to treatment outcomes in solid tumors - Select Science
Is Biodesix Inc (BDSX) worth investing in despite its overvalued state? - uspostnews.com
Market Resilience: Biodesix Inc (BDSX) Finishes Weak at 0.49, Down -2.00 - DWinneX
Biodesix partner, Friends of Cancer Research, publishes data in - GuruFocus
Biodesix and Bio-Rad Laboratories Collaborate on Research Revealing ctDNA's Role in Cancer Treatment Outcomes - Nasdaq
Biodesix partner, Friends of Cancer Research, publishes - GlobeNewswire
Major Clinical Trial Proves ctDNA Testing Accurately Predicts Cancer Treatment Outcomes in Breakthrough Study - Stock Titan
Investors Give Biodesix, Inc. (NASDAQ:BDSX) Shares A 33% Hiding - simplywall.st
Biodesix Announces Board Member Resignations - TipRanks
Biodesix, Inc. Announces Director and Committee Resignations - marketscreener.com
Samjo Management LLC Makes New Investment in Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat
Biodesix Inc [BDSX] stock was sold by Vazquez Chris at the price of US$3355.0 - knoxdaily.com
Biodesix, Inc. (NASDAQ:BDSX) Short Interest Up 29.5% in March - MarketBeat
HighTower Advisors LLC Acquires 22,500 Shares of Biodesix, Inc. (NASDAQ:BDSX) - Defense World
AIGH Capital Management LLC Buys 500,000 Shares of Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat
Closing Figures Unveiled: Biodesix Inc (BDSX) Drop -3.06, Closes at 0.61 - DWinneX
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
BDSX stock touches 52-week low at $0.63 amid market challenges - Investing.com
Perkins Capital Management Inc. Purchases 335,429 Shares of Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Biodesix, Inc. (NASDAQ:BDSX) Short Interest Update - MarketBeat
Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier - Business Wire
Biodesix, Inc. (NASDAQ:BDSX) Short Interest Up 24.6% in February - Defense World
Biodesix to Present at Cowen’s 42nd Annual Healthcare Conference - Business Wire
Biodesix chief commercial officer sells shares worth $16,198 - MSN
Q1 Earnings Estimate for Biodesix Issued By William Blair - MarketBeat
Biodesix's (BDSX) "Outperform" Rating Reaffirmed at William Blair - MarketBeat
Biodesix Inc Stock (BDSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):